Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Antoni Ribas
University of California Los Angeles, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Kite Pharma, Inc
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)
Professor Ribas will participate in data interpretation with emphasis on clinical relevance, will critically review all protocols and data, and will participate in the preparation and submission of manuscripts. He will supervise the fiscal management of the award, write progress reports, analyze and interpret all experiments, and guide the preparation and submission of manuscripts. His interest in Kite Pharma is related to this grant, which investigates NY-ESO-1 TCR. He will use NY-ESO-1 TCR that is licensed to Adaptimmune. He is on the Scientific Advisory Board.
Overcoming BRAF-inhibitor Resistance in Melanoma
RELEVANCE: The main relevance of the program is based on its translational focus to address a major scientific and clinical problem, the development of acquired resistance to BRAF inhibitors after an initial response. Program integration is achieved through the common (but non-overlapping) scientific goals of addressing resistance to BRAF inhibitors by a group of highly collaborative investigators.
Filed on June 29, 2015.
Tell us what you know about Antoni Ribas's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Antoni Ribas filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Antoni Ribas | University of California Los Angeles | Conflict of Interest | Kite Pharma, Inc. | $400,000 - $449,999 |
| Antoni Ribas | University of California Los Angeles | Conflict of Interest | Kite Pharma, Inc | Value cannot be readily determined |
| Antoni Ribas | University of California Los Angeles | Conflict of Interest | Kite Pharma, Inc. | Value cannot be readily determined |
Other search results for: “Antoni Ribas”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Antoni Ribas | University of California Los Angeles | Financial Disclosure | Merck | |
| Antoni Ribas | University of California Los Angeles | Financial Disclosure | Kite Pharma, Inc. | |
| Antoni Ribas | University of California Los Angeles | Financial Disclosure | Merck | |
| Antoni Ribas | University of California Los Angeles | Financial Disclosure | Merck | |
| Antoni Ribas | University of California Los Angeles | Financial Disclosure | Amgen | |
| Antoni Ribas | University of California Los Angeles | Financial Disclosure | Merck | |
| Antoni Ribas | University of California Los Angeles | Financial Disclosure | Merck | |
| Antoni Ribas | University of California Los Angeles | Financial Disclosure | Merck | |
| Antoni Ribas | University of California Los Angeles | Financial Disclosure | Merck |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.